MedTrace Logo

Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia

NCT01283763 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2016-11-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the non-inferiority of a topical Imiquimod therapy in patients with persistent CIN 2/3 when compared to standard therapy, i.e. conization A randomized, controlled, non-inferiority AGO-Austria trial

Conditions

  • Cervical Intraepithelial Neoplasia

Interventions

DRUG

Topical Imiquimod

16 weeks

PROCEDURE

Conization

Large loop excision of the transformation zone

Sponsors & Collaborators

  • Medical University of Graz

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • Krankenhaus Barmherzige Schwestern Linz

    collaborator OTHER

  • Salzburger Landeskliniken

    collaborator OTHER

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Stephan Polterauer, MD · Medical University of Vienna

  • Stephan Polterauer, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2017-09-30
Completion
2018-01-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01283763 on ClinicalTrials.gov